Technical Trend Overview and Price Movement
The pharmaceutical and biotechnology company, currently trading at ₹8,724.25, has seen its technical trend evolve from sideways to mildly bearish. The stock’s intraday range on 2 June 2026 spanned from ₹8,534.00 to ₹8,800.00, closing above the previous day’s close of ₹8,671.45. This slight uptick contrasts with the broader technical signals that suggest caution.
Over the past year, Astrazeneca Pharma India Ltd has delivered a 9.45% return, outperforming the Sensex’s negative 8.82% return over the same period. The stock’s longer-term performance remains impressive, with a 10-year return of 735.70%, significantly outpacing the Sensex’s 178.01%. However, recent technical shifts indicate a potential cooling off in momentum.
MACD and Momentum Oscillators Signal Divergence
The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On a weekly basis, the MACD remains mildly bullish, suggesting some upward momentum in the short term. Conversely, the monthly MACD has turned mildly bearish, signalling a weakening trend over the longer horizon. This divergence highlights the stock’s current indecision and the possibility of a correction or consolidation phase ahead.
Similarly, the Know Sure Thing (KST) indicator aligns with this mixed message: mildly bullish on the weekly chart but mildly bearish on the monthly. This oscillation between positive and negative momentum indicators underscores the need for investors to monitor developments closely before committing to a position.
RSI and Bollinger Bands: Neutral to Bullish Signals
The Relative Strength Index (RSI) on both weekly and monthly charts currently offers no definitive signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, providing no immediate impetus for a sharp move in either direction.
In contrast, Bollinger Bands on both weekly and monthly timeframes are bullish, indicating that price volatility is supporting upward price movement within the bands. This bullishness in volatility measures may provide some cushion against the bearish signals from other indicators, hinting at potential price stability or moderate gains in the near term.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Moving Averages and Volume-Based Indicators
Daily moving averages have shifted to a mildly bearish stance, reflecting recent price weakness relative to short- and medium-term averages. This suggests that the stock may face resistance in sustaining upward momentum without a catalyst.
Volume-based indicators such as On-Balance Volume (OBV) show no clear trend on either weekly or monthly charts, indicating that trading volumes have not decisively supported either buying or selling pressure. This lack of volume confirmation often precedes periods of consolidation or sideways price action.
Dow Theory and Market Context
According to Dow Theory, there is no clear trend on weekly or monthly charts, reinforcing the notion of uncertainty in the stock’s directional bias. This absence of a confirmed trend suggests that investors should exercise caution and await clearer signals before making significant portfolio adjustments.
Comparatively, Astrazeneca Pharma India Ltd’s returns have outperformed the Sensex over multiple timeframes, including a 1-month return of 6.17% versus the Sensex’s -3.44%, and a 3-year return of 149.30% compared to the Sensex’s 18.96%. Despite this strong relative performance, the current technical indicators imply a potential pause or mild correction in the stock’s upward trajectory.
Why settle for Astrazeneca Pharma India Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Analyst Ratings
Astrazeneca Pharma India Ltd currently holds a Mojo Score of 42.0, categorised as a Sell rating, downgraded from a previous Hold on 2 January 2026. This downgrade reflects the deteriorating technical outlook and the cautious stance adopted by analysts. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and risk compared to larger peers.
Investors should weigh the stock’s strong historical returns against the recent technical signals indicating a shift towards mild bearishness. The mixed signals from MACD, KST, and moving averages suggest that while short-term momentum may hold some upside, the longer-term trend is less certain.
Investment Implications and Outlook
Given the current technical landscape, Astrazeneca Pharma India Ltd appears to be at a crossroads. The mildly bearish trend on monthly indicators and daily moving averages suggests that the stock could face resistance or a period of consolidation. However, bullish Bollinger Bands and weekly MACD and KST readings provide some support for potential short-term gains.
Investors with a higher risk tolerance may consider monitoring the stock for a clearer breakout or breakdown signal, while more conservative investors might prefer to wait for confirmation of trend direction before increasing exposure. The absence of strong volume trends and neutral RSI readings further reinforce the need for caution.
Overall, Astrazeneca Pharma India Ltd’s technical profile calls for a balanced approach, recognising both its impressive long-term returns and the current signs of momentum shift.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
